Penserra Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Penserra Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,125	Closed	-$74K	–	1632
2021 Q3	$74K	Buy	1,125 +5	+0.4%	+$356	﹤0.01%	927
2021 Q2	$87K	Buy	1,120 +35	+3%	+$2.59K	﹤0.01%	840
2021 Q1	$102K	Sell	1,085 -25	-2%	-$2.97K	﹤0.01%	681
2020 Q4	$135K	Buy	1,110 +750	+208%	+$82.2K	﹤0.01%	578
2020 Q3	$31K	Buy	+360	New	+$25.1K	﹤0.01%	687

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Penserra Capital Management's TPTX Position: Q4 2021 in Review

Penserra Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2021, closing a stake of 1,125 shares — an estimated $74K sold.

Penserra Capital Management first reported a position in TPTX in Q3 2020 and held it in 5 quarters. The position peaked at $135K in Q4 2020. 172 funds tracked by Wall St. Rank hold TPTX as of Q4 2021.

Penserra Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 1,125 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $74K.
Penserra Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Penserra Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $135K in Q4 2020.
172 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.